Tanvex BioPharma, Inc. (TPE:6541)
Taiwan · Delayed Price · Currency is TWD 57.40
-2.30 (-3.85%)
Oct 23, 2025, 2:38 PM CST
Tanvex BioPharma Market Cap
Tanvex BioPharma has a market cap or net worth of 13.7 billion as of October 24, 2025. Its market cap has increased by 21.76% in one year.
Market Cap
13.70B
Enterprise Value
14.66B
Revenue
110.99M
Ranking
n/a
PE Ratio
n/a
Stock Price
57.40
Market Cap Chart
Since August 13, 2015, Tanvex BioPharma's market cap has decreased from 16.77B to 13.70B, a decrease of -18.30%. That is a compound annual growth rate of -1.96%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Oct 23, 2025 | 13.70B | 28.07% |
| Dec 31, 2024 | 10.70B | 22.75% |
| Dec 29, 2023 | 8.71B | -29.59% |
| Dec 30, 2022 | 12.38B | -39.56% |
| Dec 30, 2021 | 20.48B | 106.96% |
| Dec 31, 2020 | 9.89B | -9.41% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Caliway Biopharmaceuticals | 252.82B |
| PharmaEssentia | 186.03B |
| Bora Pharmaceuticals Co., LTD. | 77.82B |
| Lotus Pharmaceutical | 74.82B |
| Lumosa Therapeutics | 47.00B |
| Oneness Biotech | 30.13B |
| Polaris Group | 27.85B |
| Center Laboratories | 25.76B |